XML 16 R5.htm IDEA: XBRL DOCUMENT v3.25.3
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Accumulated Other Comprehensive Gain (Loss)
Balance at beginning of period (in shares) at Dec. 31, 2023   544,912,215      
Balance at beginning of period at Dec. 31, 2023 $ 247,949 $ 545 $ 1,844,988 $ (1,597,769) $ 185
Increase (Decrease) in Stockholders' Equity          
Net loss (55,390)     (55,390)  
Other comprehensive income (loss) (448)       (448)
Foreign currency translation adjustment (10)       (10)
Issuance of common stock under equity plans (in shares)   4,211,493      
Issuances of common stock under equity plans 6,749 $ 4 6,745    
Stock-based compensation related to issuances of common stock and options in exchange for services (in shares)   2,462      
Stock-based compensation related to issuances of common stock and options in exchange for services 92   92    
Issuance of common stock and pre-funded warrant to purchase common stock in public offering, net of issuance costs of $9,000 (in shares)   41,999,998      
Issuance of common stock and pre-funded warrant to purchase common stock in public offering, net of issuance costs of $9,000 141,000 $ 42 140,958    
Issuances of common stock in connection with exercise of warrants (in shares)   37,640      
Issuance of common stock in connection with exercise of warrants 49   49    
Stock-based compensation for equity-based awards to employees and directors 4,877   4,877    
Balance at end of period (in shares) at Mar. 31, 2024   591,163,808      
Balance at end of period at Mar. 31, 2024 344,868 $ 591 1,997,709 (1,653,159) (273)
Balance at beginning of period (in shares) at Dec. 31, 2023   544,912,215      
Balance at beginning of period at Dec. 31, 2023 247,949 $ 545 1,844,988 (1,597,769) 185
Increase (Decrease) in Stockholders' Equity          
Net loss (149,220)        
Foreign currency translation adjustment 17        
Balance at end of period (in shares) at Sep. 30, 2024   603,102,073      
Balance at end of period at Sep. 30, 2024 292,284 $ 603 2,037,653 (1,746,989) 1,017
Balance at beginning of period (in shares) at Mar. 31, 2024   591,163,808      
Balance at beginning of period at Mar. 31, 2024 344,868 $ 591 1,997,709 (1,653,159) (273)
Increase (Decrease) in Stockholders' Equity          
Net loss (67,383)     (67,383)  
Other comprehensive income (loss) (243)       (243)
Foreign currency translation adjustment (21)       (21)
Issuance of common stock under equity plans (in shares)   9,400,121      
Issuances of common stock under equity plans 16,373 $ 9 16,364    
Stock-based compensation related to issuances of common stock and options in exchange for services (in shares)   1,916      
Stock-based compensation related to issuances of common stock and options in exchange for services 16 $ 1 15    
Offering expenses (271)   (271)    
Issuances of common stock in connection with exercise of warrants (in shares)   281,211      
Issuance of common stock in connection with exercise of warrants 365   365    
Stock-based compensation for equity-based awards to employees and directors 12,625   12,625    
Employee stock purchases (in shares)   201,052      
Employee stock purchases 366   366    
Balance at end of period (in shares) at Jun. 30, 2024   601,048,108      
Balance at end of period at Jun. 30, 2024 306,695 $ 601 2,027,173 (1,720,542) (537)
Increase (Decrease) in Stockholders' Equity          
Net loss (26,447)     (26,447)  
Other comprehensive income (loss) 1,507       1,507
Foreign currency translation adjustment 48        
Foreign currency translation adjustment 47       47
Issuance of common stock under equity plans (in shares)   2,049,118      
Issuances of common stock under equity plans 3,574 $ 2 3,572    
Stock-based compensation related to issuances of common stock and options in exchange for services (in shares)   1,767      
Stock-based compensation related to issuances of common stock and options in exchange for services 14   14    
Issuances of common stock in connection with exercise of warrants (in shares)   3,080      
Issuance of common stock in connection with exercise of warrants 4   4    
Stock-based compensation for equity-based awards to employees and directors 6,890   6,890    
Balance at end of period (in shares) at Sep. 30, 2024   603,102,073      
Balance at end of period at Sep. 30, 2024 292,284 $ 603 2,037,653 (1,746,989) 1,017
Balance at beginning of period (in shares) at Dec. 31, 2024   606,387,666      
Balance at beginning of period at Dec. 31, 2024 280,320 $ 606 2,051,794 (1,772,341) 261
Increase (Decrease) in Stockholders' Equity          
Net loss (19,835)     (19,835)  
Other comprehensive income (loss) 55       55
Foreign currency translation adjustment (12)       (12)
Exercise of Pre-Funded Warrant (in shares)   30,369,830      
Exercise of Pre-Funded Warrant 31 $ 31      
Issuance of common stock under equity plans (in shares)   155,349      
Issuances of common stock under equity plans 256   256    
Stock-based compensation related to issuances of common stock and options in exchange for services (in shares)   4,913      
Stock-based compensation related to issuances of common stock and options in exchange for services 15   15    
Stock-based compensation for equity-based awards to employees and directors 7,408   7,408    
Balance at end of period (in shares) at Mar. 31, 2025   636,917,758      
Balance at end of period at Mar. 31, 2025 268,238 $ 637 2,059,473 (1,792,176) 304
Balance at beginning of period (in shares) at Dec. 31, 2024   606,387,666      
Balance at beginning of period at Dec. 31, 2024 280,320 $ 606 2,051,794 (1,772,341) 261
Increase (Decrease) in Stockholders' Equity          
Net loss (54,638)        
Foreign currency translation adjustment 65        
Balance at end of period (in shares) at Sep. 30, 2025   638,355,275      
Balance at end of period at Sep. 30, 2025 248,707 $ 638 2,074,640 (1,826,979) 408
Balance at beginning of period (in shares) at Mar. 31, 2025   636,917,758      
Balance at beginning of period at Mar. 31, 2025 268,238 $ 637 2,059,473 (1,792,176) 304
Increase (Decrease) in Stockholders' Equity          
Net loss (16,375)     (16,375)  
Other comprehensive income (loss) (191)       (191)
Foreign currency translation adjustment 4       4
Issuance of common stock under equity plans (in shares)   509,072      
Issuances of common stock under equity plans 591 $ 1 590    
Stock-based compensation related to issuances of common stock and options in exchange for services (in shares)   5,540      
Stock-based compensation related to issuances of common stock and options in exchange for services 26   26    
Stock-based compensation for equity-based awards to employees and directors 6,738   6,738    
Employee stock purchases (in shares)   417,369      
Employee stock purchases 500   500    
Balance at end of period (in shares) at Jun. 30, 2025   637,849,739      
Balance at end of period at Jun. 30, 2025 259,531 $ 638 2,067,327 (1,808,551) 117
Increase (Decrease) in Stockholders' Equity          
Net loss (18,428)     (18,428)  
Other comprehensive income (loss) 218       218
Foreign currency translation adjustment 73       73
Issuance of common stock under equity plans (in shares)   499,834      
Issuances of common stock under equity plans 542   542    
Stock-based compensation related to issuances of common stock and options in exchange for services (in shares)   5,702      
Stock-based compensation related to issuances of common stock and options in exchange for services 29   29    
Stock-based compensation for equity-based awards to employees and directors 6,742   6,742    
Balance at end of period (in shares) at Sep. 30, 2025   638,355,275      
Balance at end of period at Sep. 30, 2025 $ 248,707 $ 638 $ 2,074,640 $ (1,826,979) $ 408